82586-62-7

Usage

Chemical Properties

White Solid

Uses

Different sources of media describe the Uses of 82586-62-7 differently. You can refer to the following data:
1. Moexipril intermediate
2. Moexipril intermediate.

InChI:InChI=1/C12H15NO4.ClH/c1-16-10-4-7-3-9(12(14)15)13-6-8(7)5-11(10)17-2;/h4-5,9,13H,3,6H2,1-2H3,(H,14,15);1H/t9-;/m0./s1

Upstream product

• 50-00-0 formaldehyd 
• 69274-24-4 (S)-2-amino-3-(3,4-dimethoxyphenyl)propanoic acid hydrochloride 
• 25349-37-5 (Z)-2-phenyl-4-(3,4-dimethoxybenzylidene)-(4H)-1,3-oxazol-5-one 
• 76313-29-6 methyl (Z)-2-benzoylamino-3-(3,4-dimethoxyphenyl)-2-propenoate 
• 109278-11-7 (S)-(+)-methyl 2-benzoylamino-3-(3,4-dimethoxyphenyl)propanoate 
• 120-14-9 3,4-dimethoxy-benzaldehyde 
• 358627-67-5 (S)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-(tert-butyloxycarbonyl)-3-isoquinolinecarboxylic acid 
• 138908-56-2 (S)-(+)-2-tert-butoxycarbonylamino-3-(3,4-dimethoxyphenyl)propionic acid methyl ester 
• 32161-30-1 (S)-3,4-dimethoxyphenylalanine 
• 617699-47-5 (S)-1,2,3,4-tetrahydro-6,7-dihydroxy-2-(tert-butyloxycarbonyl)-3-isoquinolinecarboxylic acid 

Downstream Products

• 103733-32-0 (S)-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, phenylmethylester, hydrochloride 
• 103733-66-0 tert-butyl (S)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylate 

Relevant academic research and scientific papers

Continuous Flow Synthesis of ACE Inhibitors From N-Substituted l-Alanine Derivatives

A strategy for the continuous flow synthesis of angiotensin converting enzyme (ACE) inhibitors is described. An optimization effort guided by in situ IR analysis resulted in a general amide coupling approach facilitated by N-carboxyanhydride (NCA) activation that was further characterized by reaction kinetics analysis in batch. The three-step continuous process was demonstrated by synthesizing 8 different ACE inhibitors in up to 88 % yield with throughputs in the range of ≈0.5 g h?1, all while avoiding both isolation of reactive intermediates and process intensive reaction conditions. The process was further developed by preparing enalapril, a World Health Organization (WHO) essential medicine, in an industrially relevant flow platform that scaled throughput to ≈1 g h?1.

An organogel formed from a cyclic β-aminoalcohol

A new organogelator with unique structural feature of a cyclic β-aminoalcohol is presented as the first example of gelation by aminoalcohol through hydrogen-bonding between hydroxy and amine.

Preparation of chiral 1,2,3,4-tetrahydro-6,7-dialkoxy-3-isoquinolinecarboxylic acid and derivatives

The present invention relates to a process for the production of (S)-1,2,3,4-tetrahydro-6,7-dialkoxy-3-isoquinolinecarboxylic acid compounds (1) and their derivatives from Levodopa (L-Dopa). The ultimately prepared compounds are used as intermediates for, but not limited to, the preparation of substituted derivatives of 1,2,3,4-tetrahydro-6,7-dialkoxy-3-isoquinolinecarboxylic acid wherein R1is hydrogen, lower alkyl, C2-C12 acyl, or R1O together are methylenedioxy; R2is hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, substituted aryl, aralkyl or substituted aralkyl group; and R3is hydrogen, C2-C12 acyl group, benzyl, alkoxylcarbonyl group, or aralkoxyl carbonyl group.

PREPARATION OF CHIRAL 1,2,3,4-TETRAHYDRO-6,7-DIALKOXY-3-ISOQUINOLINECARBOXYLIC ACID AND DERIVATIVES BY REACTING LEVODOPA WITH FORMALDEHYDE OR FORMALDEHYDE PRECURSORS

A process for preparation of (S)-1,2,3,4-tetrahydro-6,7-dialkoxy-3-isoquinolinecarboxylic acid compounds and their derivatives of the formula (1) the process compring: (i) reacting Levodopa of formula (2) with formaldehyde or formaldehyde precursors to obtain (S)-1,2,3,4-tetrahydro-6,7-dihydroxy-3-isoquinolinecarboxylic acid of formula (3); (ii) protecting the amino group of formula (3); (iii) alkylating the phenol groups of formula (4) to form compound of formula (5); and (iv) esterifying the carcoxylic acid of formula (5) and optionally removing N-protecting group wherein R1 is hydrogen, lower alkyl, C2-C12 acyl, or R1O together are methylenedioxy; R2 is hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, substituted aryl, aralkyl or substituted aralkyl group; R3 is hydrogen, C2-C12 acyl group, benzyl, alkoxylcarbonyl group, or aralkoxyl carbonyl group; wherein P is the protecting group selected from alkoxycarbonyl, acyl, alkyl, aryl, siryl, sulfenyl and sulfonyl.